Form 4 for IDXX Idexx Laboratories
Accepted 2023-05-05 00:00:00 ET · period of report 2023-05-04 · accession 0000874716-23-000038 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-05 | 2023-05-04 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | $178.26 | +560 | 73.3K | +0.8% | +$99.8K |
| D | 2023-05-05 | 2023-05-04 | IDXX | MAZELSKY JONATHAN JAY | Pres, CEO, Dir | M - OptEx | — | -560 | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-04 | M | A | 560 | $178.26 | 73,301.35 | D | — | — | (F1) Includes 14.7030 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2023. |
| 2 | Derivative | Incentive Stock Option (right-to-buy) | 2023-05-04 | M | D | 560 | — | 0 | D | $178.26 · — to 2028-02-13 | 560 Common Stock | (F3) Not applicable. (F2) Grant of option to buy shares of Issuer common stock that became exercisable on the fifth anniversary of the date of grant. |